NTIBO

About the company

NTIBO develops AI-driven drug discovery for difficult-to-target proteins implicated in neurodegeneration, cancer, and aging. Traditional methods fail because these proteins lack fixed structures—our platform uses complementary proteases mapping and deep learning (CNN achieving MCC 0.62) to identify where drugs can bind.

We validate therapeutic peptides using AlphaFold3, achieving gold-standard confidence. 4 patents filed (5th in development), quantum-enhanced optimization in development with IBM. Strategic partnerships: IBM Partner Plus, Arrow Electronics funding. Focus: ALS/FTD, Parkinson's, Alzheimer's, SIRT6 longevity pathways. Platform applicable to 30-50% of human proteome previously considered undruggable.

Quick links:

Website: www.ntibo.com

Demo video: In production (available Q4 2025)

Pitch Deck See attached presentation (PDF) and Notion link

Technical Validation: 4 patents filed (5th in development/ PRV Sweden), CNN MCC 0.62, AlphaFold3 IPTM 0.59

Contact:

Patrik Artell, Founder & CEO

Email: patrik@ntibo.com

Phone: +46 708 325 873

Capital need and valuation:

Capital Need: €500,000 (verification funding round)

Pre-Money Valuation: Startup

Experimental validation (€200k): Synthesize and test peptides identified by platform

Quantum optimization development (€150k): IBM partnership, TechXchange demonstrations

Team expansion (€100k): Computational biologist + wet-lab lead

Patent prosecution (€50k): International PCT filing for 4(5) patents

Financial forecast

Estimated Turnover 2025: €0 (pre-revenue, verification stage)

Estimated Turnover 2026: €200,000 (pharma partnership pilots)

Revenue Model:

Platform licensing to pharmaceutical companies

Co-development partnerships (milestone payments + royalties)

Target validation services for IDR therapeutics

Previous investments

Founders have invested: €50,000 (bootstrapped development)
External investors: €0 (seeking first institutional round)
In-kind support: Arrow Electronics (GPU compute credits + TechXchange sponsorship)

Vision & Impact

Long-term vision: Become the leading platform for IDR-targeted therapeutics, addressing neurodegenerative diseases affecting 50+ million people globally.

UN SDG alignment:

SDG 3 (Good Health): Novel therapeutics for ALS, Parkinson's, Alzheimer’s
SDG 9 (Innovation): Quantum-enhanced drug discovery methodology
SDG 17 (Partnerships): Collaboration with IBM, academic institutions, pharma
Impact thesis: IDRs represent 30-40% of human proteome but <1% of approved drug targets. NTIBO's platform unlocks this "dark matter" of drug discovery, potentially creating €10B+ market for IDR therapeutics by 2035.

Risk Management

Identified Risks:

Technology risk: CNN validation (MCC 0.62) may not translate to wet-lab success
Mitigation: AlphaFold3 gold-standard validation (IPTM 0.59) provides orthogonal confirmation. Experimental validation funded in current round.
Market risk: Pharmaceutical industry slow adoption of AI-driven discovery
Mitigation: IBM partnership provides enterprise credibility. Focus on licensing model (low customer acquisition friction).
Regulatory risk: Peptide therapeutics face complex approval pathways
Mitigation: Partner with established pharma for clinical development. NTIBO remains discovery platform, not drug developer.
IP risk: Patent prosecution uncertainty for AI/computational methods
Mitigation: 4 complementary patents filed covering different aspects of platform. Swedish PRV filing establishes priority dates. PCT international filing planned 2026.
Competition risk: AlphaFold3, other AI drug discovery platforms
Mitigation: NTIBO's unique positioning: only platform combining protease validation + AI prediction + quantum optimization specifically for IDRs. AlphaFold3 is complementary tool, not competitor. NTIBO addresses specific IDR conformational sampling gaps that structure-prediction models cannot capture.